Skip to main content
Fig. 5 | Stem Cell Research & Therapy

Fig. 5

From: Long term outcomes of intracarotid arterial transfusion of circulatory-derived autologous CD34 + cells for acute ischemic stroke patients—A randomized, open-label, controlled phase II clinical trial

Fig. 5

Images from brain perfusion single-photon emission computed tomography (SPECT) studies using 99mTc-labeled radiopharmaceuticals A and B Images indicating the baseline (A) prior to and 6 months (B) after CD34 + T-cell therapy in the cell-treated group (G1). C and D Baseline (C) and 6-month follow-up (D) data after acute ischemic stroke without CD34 + cell therapy in the control group (G2) (i.e., the control group). In the cell-treated group, the results of Tc-99 m ECD brain perfusion SPECT revealed that, compared with that at baseline, brain perfusion (white arrows) was notably increased by 6 months after CD34 + T-cell therapy. On the other hand, in the control group, compared with that at baseline, brain perfusion (white arrows) was markedly decreased at 6 months after acute ischemic stroke

Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512